Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30800272 | 1.00 | ACHE (0.31) | ACHE | |
| SCHEMBL29483958 | 0.93 | ALDH1A1 (0.32) | — | |
| SCHEMBL1605121 | 0.93 | ALDH1A1 (0.32) | — | |
| SCHEMBL6995721 | 0.86 | — | — | |
| SCHEMBL5690738 | 0.83 | MAPK1 (0.30) | — | |
| SCHEMBL9419963 | 0.79 | — | — | |
| Trifluoromethanesulfonic Acid SCHEMBL7978113 | 0.78 | PTPN1 (0.33) | — | |
| Trifluoromethanesulfonic Acid SCHEMBL29483957 | 0.78 | GPR3 (0.44) | ACHE | |
| SCHEMBL6757022 | 0.74 | KIF11 (0.31) | — | |
| SCHEMBL5074761 | 0.71 | ACHE (0.38) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4457212-B1 | METHOD FOR PREPARING IONIC COMPOUNDS | FUNDACION CENTRO DE INVESTIG COOPERATIVA DE ENERGIAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2025-12-10 | — | — | EP | claimed |
| US-20250066294-A1 | METHOD FOR PREPARING IONIC COMPOUNDS | FUNDACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA DE ENERGÍAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2025-02-27 | — | — | US | claimed |
| EP-4457212-A1 | METHOD FOR PREPARING IONIC COMPOUNDS | Fundación Centro de Investigación Cooperativa de Energías Alternativas, CIC Energigune Fundazioa (ES) | 2024-11-06 | — | — | EP | claimed |
| WO-2023126377-A1 | METHOD FOR PREPARING IONIC COMPOUNDS | FUNDACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA DE ENERGÍAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2023-07-06 | — | — | WO | claimed |
| US-20220204509-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | Epitas Biosciences (shanghai) Co., Ltd. (CN) | 2022-06-30 | — | — | US | claimed |
| EP-3967691-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | Epitas Biosciences (Shanghai) Co., Ltd. (CN) | 2022-03-16 | — | — | EP | claimed |
| JP-3197479-A | — | — | None | — | — | JP | disclosed |
| US-20250388561-A1 | A BICYCLOPENTYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2025-12-25 | — | — | US | disclosed |
| EP-4457212-B1 | METHOD FOR PREPARING IONIC COMPOUNDS | FUNDACION CENTRO DE INVESTIG COOPERATIVA DE ENERGIAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2025-12-10 | — | — | EP | disclosed |
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250087747-A1 | SOLID POLYMER ELECTROLYTES COMPRISING IONIC COMPOUNDS AND USES THEREOF | FUNDACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA DE ENERGÍAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2025-03-13 | — | — | US | disclosed |
| US-20250066294-A1 | METHOD FOR PREPARING IONIC COMPOUNDS | FUNDACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA DE ENERGÍAS ALTERNATIVAS CIC ENERGIGUNE FUNDAZIOA (ES) | 2025-02-27 | — | — | US | disclosed |
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-02-20 | — | — | US | disclosed |
| EP-1642172-A2 | COMPOSITIONS COMPRISING PHOTOACID GENERATORS | AZ Electronic Materials USA Corp. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005003858-A2 | COMPOSITIONS COMPRISING PHOTOACID GENERATORS | AZ ELECTRONIC MATERIALS USA CORP. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20040265733-A1 | Photoacid generators | AZ ELECTRONIC MATERIALS USA CORP. | 2004-12-30 | — | — | US | disclosed |
| EP-0382206-B1 | Perfluoroalkyl-containing compound | SAGAMI CHEM RES (JP) | 1994-10-26 | — | — | EP | disclosed |
| US-5066795-A | Reagent for perfluoroalkylation, heterocyclic sulfur or selenium compounds | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-11-19 | — | — | US | disclosed |
| JP-H03197479-A | (PERFLUOROALKYL)DIBENZONIUM SALT AND INTERMEDIATE FOR PRODUCING THE SAME | SAGAMI CHEM RES CENTER | 1991-08-28 | — | — | JP | disclosed |
| EP-0382206-A1 | Perfluoroalkyl-containing compound | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340574-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ACHE 4855/4885 |
| US-20250059196-A1 | TRICYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, CYP51A1, WEE2 | ACHE 1214/4885 |
| US-20220204509-A1 | PYRIMIDO FIVE-MEMBERED HETEROCYCLIC COMPOUND AND USE THEREOF AS MUTANT IDH2 INHIBITOR | IDH2, IDH1, IDH3A | ACHE 3916/4885 |
| US-20250388561-A1 | A BICYCLOPENTYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | BACE1, BACE2, CYP3A43 | ACHE 368/4885 |
| US-20250066294-A1 | METHOD FOR PREPARING IONIC COMPOUNDS | TST, MRPS23, SRMS | ACHE 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.